Candel reports prostate cancer drug's long-term data ahead of FDA filing

Candel Therapeutics has released long-term follow-up data for its prostate cancer drug, which is set to be submitted for FDA marketing approval later this year. This data could strengthen the company's position as it seeks regulatory approval.